Protocol Ledger

NCT05416307 · Phase II/III · RECRUITING

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Interventional Phase II/III clinical trial protocol NCT05416307 sponsored by Electra Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-19 Enrollment: 156 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05416307
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)156 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05416307
Protocol FieldVerified Registry Value
NCT IdentifierNCT05416307
Consolidated Lead SponsorElectra Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment156 participants (ESTIMATED)
Registered Start Date2022-05-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI